These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24317477)

  • 1. Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
    Omura T; Shimada Y; Nagata T; Okumura T; Fukuoka J; Yamagishi F; Tajika S; Nakajima S; Kawabe A; Tsukada K
    Oncol Rep; 2014 Feb; 31(2):613-8. PubMed ID: 24317477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
    Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
    Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
    Hasegawa H; Fujitani K; Kurokawa Y; Hirao M; Nakazuru S; Mita E; Tsujinaka T
    Chemotherapy; 2010; 56(6):436-43. PubMed ID: 21088394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical significance of the human epidermal growth factor receptor 2( HER2) in patients with recurrent gastric cancer who received S-1 adjuvant chemotherapy].
    Aoyama T; Hayashi T; Fujikawa H; Ogata T; Cho H; Wada H; Kitani Y; Yukawa N; Oshima T; Rino Y; Ozawa Y; Masuda M; Yoshikawa T
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1647-9. PubMed ID: 24393876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
    Ichikawa W; Terashima M; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):263-273. PubMed ID: 26884344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Impact of adjuvant chemotherapy in patients with T1N2/3 Gastric cancer].
    Tsuchida K; Kunisaki C; Watanabe T; Ono H; Oshima T; Fukushima T; Yoshikawa T; Rino Y; Imada T; Masuda M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2239-41. PubMed ID: 25731482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
    Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
    Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
    Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
    Sakurai Y; Kamoshida S; Furuta S; Sunagawa R; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1147-55. PubMed ID: 18633253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy.
    Ishido K; Azuma M; Koizumi W; Takeuchi A; Sakuramoto S; Watanabe M; Okayasu I
    Pharmacogenet Genomics; 2009 Dec; 19(12):955-64. PubMed ID: 19898266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
    Ito S; Ohashi Y; Sasako M
    BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of adjuvant chemotherapy with S-1 for gastric cancer patients].
    Kitagawa M; Ichikawa D; Okamoto K; Shiozaki A; Fujiwara H; Kuriu Y; Ikoma H; Nakanishi M; Ochiai T; Sakakura C; Kokuba Y; Sonoyama T; Otsuji E
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1917-9. PubMed ID: 20948256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
    Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
    Takebayashi K; Kawai Y; Tagi T; Matsumura M; Shimizu K; Yamamoto H; Mekata E; Tani T; Sato M
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):385-7. PubMed ID: 22421764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
    Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
    Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicobacter pylori infection is associated with favorable outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy.
    Nishizuka SS; Tamura G; Nakatochi M; Fukushima N; Ohmori Y; Sumida C; Iwaya T; Takahashi T; Koeda K;
    J Surg Oncol; 2018 Apr; 117(5):947-956. PubMed ID: 29355977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of body weight loss in gastrectomy patients who underwent only surgery and those who underwent surgery followed up with S-1 adjuvant chemotherapy].
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Ogata T; Cho H; Yukawa N; Oshima T; Rino Y; Ozawa Y; Kitani Y; Wada H; Masuda M; Tsuburaya A
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):1794-6. PubMed ID: 23267889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer.
    Aoyama T; Sato T; Maezawa Y; Kano K; Hayashi T; Yamada T; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
    Int J Clin Oncol; 2017 Jun; 22(3):476-483. PubMed ID: 28176023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.